Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Takeda (Tokyo:4502) said a planned 2Q08 NDA submission for lapaquistat (TAK-475)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury